MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- SUN PHARMA
SUN PHARMA Share Price (SUNP)
Here is the latest stock price and chart of Sun Pharma. For more details, see the Sun Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Only Till 11:59PM, Tomorrow: Access Details of Our Top Stock Pick for 2021
| Live BSE Quotes | Sep 29, 2020 03:37:00 PM | ||
|---|---|---|---|
| Price (Rs)504.65 | Open (Rs) 516.25 | High (Rs) 516.60 | Low (Rs) 504.65 |
| % Change-1.09 | Volume 362,073 | Value (Rs) 182,720,139 | 52-Week H/L 564.90 / 315.20 |
| Live NSE Quotes | Sep 29, 2020 3:29:59 PM | ||
|---|---|---|---|
| Price (Rs)505.20 | Open (Rs) 517.85 | High (Rs) 517.85 | Low (Rs) 504.50 |
| % Change-0.96 | Volume 8,591,884 | Value (Rs) 4,379,283,275 | 52-Week H/L 564.75 / 312.00 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -1.09% | 1 Month -2.67% | 3 Months 4.74% | 1 Year 29.51% | 5 Years (CAGR)* -9.91% | 10 Years (CAGR)* 9.69% |
* Compound Annual Growth Rate
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 1.06 | P/E Ratio (x) 475.18 | Market Cap (Rs m) 1,214,567.90 | P/BV (x) 2.93 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
SUN PHARMA Share Price Today:
SUN PHARMA last traded price was down 1.1% to Rs 504.7 on the BSE. On the NSE, SUN PHARMA last traded price was down 1.0% to Rs 505.2. The total volume of shares traded was 9.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.6%. And the benchmark S&P BSE SENSEX was at 37,973.2 (down 0.0%).
Over the last 30 days, the SUN PHARMA share price is down 3.9%. And over the last one year, SUN PHARMA share price is up 24.1%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
Today's Market
Indian Indices End on a Flat Note; Telecom and Banking Stocks Witness Selling(Closing)
Indian share markets continued to witness volatile trades during closing hours today and ended on a flat note.
Related Views On News
SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)
May 28, 2020 | Updated on May 28, 2020For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)
Feb 7, 2020 | Updated on Feb 7, 2020For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsMost Popular
Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)
Sep 17, 2020This leading household brand will profit big time in a post covid world.
My Top Stock to Buy in this Market Selloff (Profit Hunter)
Sep 22, 2020The recent correction offers a great opportunity to buy this high conviction smallcap stock.
Can the Nifty Fall to 10,200? (Fast Profits Daily)
Sep 24, 2020The Nifty has reached an important support level today. If it breaks then we could see further downside.
What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)
Sep 18, 2020Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...
MoreOUR TOP 5 IDEAS
- REVEALED: 5 Pandemic-Proof Smallcaps You Should Know About...
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA - ACTAVIS COMPARISON
COMPARE SUN PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.